United States:
The Future Of Prenatal Molecular Diagnostics: Impact Of The Changing Patent Landscape
19 January 2014
Fox Rothschild LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Recent developments in US patent law will provide both
challenges and opportunities for creating effective intellectual
property and commercialization strategies for prenatal molecular
diagnostic methods and may ultimately influence provider and
patient access to certain tests.
In Mayo v. Prometheus [1], the US Supreme Court
addressed the legal standards for patent-eligible subject matter
under 35 USC §101, with important implications for patents
directed to diagnostic methods.
To view the full text, click here.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.